Partner With Us NRI

Company details

6M Return 4.15%
1Y Return -17.98%
Mkt Cap.(Cr) 29,597.73
Volume 54,014
Div Yield 0.37%
OI Chg %
Volume 54,014

Open Free Demat Account Online with ICICIDIRECT


  • swot

  • technicals

  • deals

  • shareholding


Delivery and volume

Our Research View

Trading recommendation

Data not found

Investment recommendation

Call Date

28 Jul 2022

Entry Price


Target Price



12-18 Month

Rapid Results

Q1FY23 Quarterly Result Announced for Laurus Labs Ltd.

Pharmaceuticals firm Laurus Labs Announced Q1FY23 Result :

  • Revenue at Rs 1,539 crs, up 20% (YoY)
  • EBITDA Rs 454 crs, increased by 14% (YoY)
  • EBITDA margins at 29.5%
  • PAT at Rs 251 crs, increased by 4% (YoY)
  • PAT margins at 16.3%
  • EPS (Diluted) for the period at Rs 4.7 per share (not annualised)

Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated “Laurus Lab's performance in the first quarter of the current financial year reflects our efforts towards strengthening and diversifying our business by an increased focus on Non-ARV APIs and Formulations and high-growth CDMO segments. This strong momentum has been delivered because of our efforts toward a sustainable supply chain, capacity creation, and on-time delivery of products during the current challenging environment. Pricing pressure in ARV APIs and the Formulation business was significant during this quarter, and ARV FDF volumes would increase in the coming quarters. The high-margin CDMO business growth helped the organization deliver very good revenue and profit.

Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said; “In Q1 FY23, Laurus Lab has continued its strong performance with 20% revenue growth to Rs 1,539 crs, driven by solid growth in our CDMO-Synthesis business. EBITDA came at Rs 454 crs with consistent EBITDA margins of 29.5% as better mix more than offset for depressed pricing in ARV business. Our ROCE on annualised basis stood healthy ~29.4% with comfortable Balance sheet position. In Q1, Laurus Lab invested a total of Rs 209 crs Capex and we are on track to execute on our future capex schedule”.

Result PDF


  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio


Operating Profit(Cr.)

Profit after Tax(Cr.)


Reserves and Surplus



Operating Profit

Profit after tax





Equity Capital: 3,351.19 Cr FV: 2.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 2,384.58 23,141.09
LAST 3M 49,521.50 -18,551.54
LAST 6M 129,719.68 -157,153.27
LAST 12M 215,295.98 -222,611.80
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
May 10, 2022 Dividend 60
Nov 17, 2021 Dividend 40
May 11, 2021 Dividend 40


  • About Company
  • Company Info
  • Listing Info
  • Laurus Labs Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 37508.48 crores, it is incorporated in the year 2005. It features consolidated sales of Rs. 1220.60 crores in June 2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 540222 and additionally listed in the National Stock Exchange (NSE) with the code LAURUSLABS.

    Laurus Labs is one of the top pharmaceuticals companies in the country, holding a leadership position in research & development and manufacturing of generic APIs. The company is also working with several top pharmaceuticals companies worldwide for research & development with a primary focus on anti-retroviral, Hepatitis C, and Oncology drugs. The company also owns around 155 patents. The headquarters of Laurus labs are situated in the city of Hyderabad, while its manufacturing plants are located in Visakhapatnam, Hyderabad, and Bengaluru. Laurus Labs has also received several approvals from major regulatory medical bodies worldwide, such as WHO, USFDA, KFDA, MHRA, etc. In March’20, Laurus Labs received approval from USFDA for hydroxychloroquine tablets, which were initially used to treat the COVID-19 patients. The promoters within the company currently hold 53.56% of the stake in the company, while the Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) hold 6.65% and 3.44% of the stake. The balance of 36.35% is by others (retail investors).

    In June 2021, quarterly net sales were Rs. 1,220.6 crores, which has increased by approximately 25.78% from Rs. 970.4 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 222.08 crores, which has grown by 39.87% from a net profit of Rs. 158.78 crores in June 2020. In June 2021, operating profit was reported at Rs. 1,032.11 crores, which is also increased by 25.79% as compared to an operating profit of Rs. 820.49 crores for the quarter ending in June 2020. From Rs. 2.97 in June 2020, the EPS of Laurus Labs has grown to just Rs. 4.14 per share in June 2021. LAURUSLABS’s stock closed at Rs. 689.35 on 16th August’2021 (NSE) and has returned 86.97% in the last six months and 234.49% within the last year.

Read More

Registered Address

Plot No 21 Jawaharlal Nehru, Pharma City Parawada, Visakhapatnam, Andhra Pradesh, 531021

Tel : 91-891-3061222
Email : secretarial:lauruslabs.com
Website : http://www.lauruslabs.com


KFin Techologies Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 540222
Book Closure Date (Month) : Jul
BSE Group : A
ISIN : INE947Q01028

ICICIdirect Laurus Labs Ltd FAQ

You can buy Laurus Labs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Laurus Labs Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Aug 08, 2022 04:01 PM the closing price of Laurus Labs Ltd was ₹ 550.80.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Aug 08, 2022 04:01 PM, the market cap of Laurus Labs Ltd stood at ₹ 29,597.73.
The latest PE ratio of Laurus Labs Ltd as of Aug 08, 2022 04:01 PM is 35
The latest PB ratio of Laurus Labs Ltd as of Aug 08, 2022 04:01 PM is 0.11
The 52-week high of Laurus Labs Ltd is ₹ 723.55 while the 52-week low is ₹ 433.20 .
According to analyst recommendations, Laurus Labs Ltd has a “Buy” rating for the long term.

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote